N
EURAL transplantation was initially perceived as an experimental tool for the systematic study of neural development and regeneration, particularly in invertebrate species where regenerative capacities are most robust. Initial examination of this question in mammals invariably relied upon the same rationale (that is, that this represented an excellent means of studying basic neural mechanisms). This rationale shifted dramatically when several groups of investigators discovered that a variety of neurological deficits could be improved with neural grafting, particularly if the donor cells were derived from fetal brain. Thus, consistent graft-induced alterations in motor, sensory, cognitive, and endocrine parameters in rodents prompted considerable speculation that similar procedures might prove effective clinically, especially in Parkinson's disease which in part is characterized by a welldefined transmitter deficit. This coupled with the fact that many parkinsonian patients become refractory to pharmacological intervention has led to the search for more optimal therapeutic approaches.
This contribution is the 31st in a series of review articles selected jointly by the Committee on Graduate Education of the American Association of Neurological Surgeons and the Congress of Neurological Surgeons, and the Journal of Neurosurgery. --Editor.
The First 80 Years: 1890-1970
The initial attempts at neural grafting, as reviewed in detail by Gash 23 and Bj6rklund and Stenevi, 5 are attributed to W. Gilman Thompson of New York University, who in 1890 published a brief report on his experiments on the transplantation of cerebral cortex derived from adult cats into adult dogs. 69 Although his attempts were largely unsuccessful as judged by somewhat insensitive histological techniques employed at that time, he probably drew attention to the first of four basic questions that are inherent in all neural grafting experiments. Specifically, he asked whether nerve cells could survive following placement into a host brain. In 1903, two new lines of experimentation began, one by S. Saltykow at the University of Basel and the other by Elizabeth H. Dunn at the University of Chicago. In 1905, Saltykow ~8 reported survival of neurons for as long as 8 days following autografts of cerebral cortex in young rabbits; thereafter, progressive signs of degeneration were in evidence. Dunn J 3 published her results in 1917 on grafting cerebral cortex from embryonic rats into cavities in littermate hosts. She noted survival of grafts whenever they were juxtaposed to the choroidal plexus of the lateral ventricles. She also noted retention of the organotypic appearance of grafted cortex which, along with her observations on the survival and probable need for vascularization, remain as key principles in the field.
Somewhat concurrently, S. Walter Ranson at Northwestern University reported on the successful grafting of spinal ganglia from neonatal rats into the cerebral cortex of adult host rats. 53' $4 Ranson published his findings in 1909 and 1914 at the beginning of his distinguished career as a neuroanatomist. One wonders parenthetically if the field of neural grafting research would have advanced more rapidly had Professor Ranson chosen to pursue his initial experiments on grafting to the extent that he pursued the quest for identifying novel neural pathways. Numerous additional examples can be found of early grafting experiments in the studies of Del Conte, ~2 Tello, 68 Faldino, ~6 and others.
Sporadic reports appeared over the next 30 to 40 years that are perhaps highlighted by two important studies. In 1940, W. E. LeGros Clark of Oxford 34 demonstrated unequivocally that fetal grafts possessed the greatest potential for the establishment Of adult-like laminar and cellular patterns, which ultimately may prove to be of the highest significance with respect to therapeutic interventions, as explored below. In 1957, Flerk6 and Szent~gothai, ~8 in a neuroendocrinological experiment, discovered the usefulness of the ventricular system as a site for promoting graft survival and growth, thus confirming Dunn's earlier observation. Endocrinologically active tissue was placed into the third ventricle where it showed excellent survival. Halfisz, et al., 29'3~ pursued these experiments and provided the first evidence of a functional interaction between grafted tissue and host brain by reversing endocrine deficits produced in hypophysectomized rats. This basic paradigm was extensively utilized later by the present authors to explore the potential for functional intervention following grafting of fetal vasopressin neurons into rats exhibiting diabetes insipidus, as described below under Exploration of Models, 1980 Models, -1985 In 1945, R. M. May 42 drew attention to two important phenomena. First, he demonstrated that the anterior chamber of the eye provided an excellent environment for neural grafting; after insertion of the graft through a small incision in the host's cornea, graft growth could be followed simply by direct observation. Some of May's important observations included the demonstration that co-grafts of cerebral tissue and peripheral nerve resulted in an apparent growth of axons from central neurons toward and into the degenerating peripheral axon. In a subsequent experiment he cografted cerebellum and striated muscle and noted that the muscle became innervated by the fibers, which formed connections comparable (at the light microscopic level) to the neuromuscular endings seen in situ. 4~ These pivotal observations supported the concept that grafts were capable of providing a form of innervation and that elements in the tissue could induce growth, which perhaps led to the subsequent search for trophic factors that promote and maintain graft-host integration. Although numerous other studies were performed during this period of time, as reviewed extensively by Gash 23 and Bj6rklund and Stenevi, 5 the studies cited above established the feasibility of nerve-cell grafting as a means of studying the developing nervous system and its integration, for example, with the periphery. It was clear from these investigations that fetal and embryonic central nervous system (CNS) tissue possesses the best survival characteristics and that adequate vascularization is an essential prerequisite for graft viability. Importantly, the cytoarchitectonic patterns of cells and the fiber projections could be maintained in host brain following grafting of selected regions, primarily cerebral cortex, of the CNS. In spite of these essential first findings, countless questions remained (and still remain) with respect to optimal technical approaches, intriguing models of neurodegenerative disorders, and potential applications to neural dysfunctions.
A Decade of Discovery: 1970-1979
The next era actually may have begun (unknowingly) in 1962, when Bengt Falck, Nils-Ake Hillarp, and their coworkers published their now classic contribution on the use of formaldehyde vapors to condense primary and secondary monoamines into fluorogenic substances. ~5 This formaldehyde-induced fluorescence allowed the identification of the monoamine neurotransmitters, dopamine, norepinephrine, and serotonin, within nerve-cell bodies and their terminal axons. It is noteworthy that two of the then students of Professors Falck (Anders Bj6rklund) and Hillarp (Lars Olson) have subsequently employed this histochemical procedure in elegant studies to examine and understand grafted neural tissue. Olson at the Karolinska Institute and Bj6rklund at the University of Lund have independently continued transplantation studies, utilizing histochemical techniques to analyze grafted neurons, which have revolutionized our understanding of neural plasticity and regeneration. Each laboratory has essentially taken advantage of the fact that the histofluorescence methods could reveal aspects of developing and regenerating neurons which were difficult and often impossible to visualize by more classic approaches. This, coupled with the fact that monoamine neurons are extremely plastic 3' 45' 46' 5~ and can be identified early in development because of the expression of their transmitter phenotype, 35' 51 has promoted the use of monoamine cell grafts to study critical issues in transplantation. These questions include identification of optimum donor age, grafting techniques ( Fig. 1) , electrical properties (Fig. 2) , duration of graft survival, connections with co-grafts and/or host brain, and ultimately, functional interactions with and influence on the host brain. 6, 19, 21, 31, 60, 67 In the 1970's, the principal focus was given to four basic questions related to transplantation. growth patterns with respect to size, shape, and geometric cytoarchitectonic arrangements? If so, successful grafts could be expected to develop an organotypic appearance with respect to the spatial relationships of cells and fibers, often producing, for example, a laminar appearance for cerebral cortex or a typical arrangement of pyramidal cells in hippocampus. Third, if cells survive, do they extend dendritic and axonal processes throughout the graft and into the host brain? This also encompasses the question of reciprocal connectivity wherein potential afferent information may reach grafted cells via a plastic response of the host (usually adult) brain. The question of ultrastructural connectivity is also raised under this basic question. Fourth, if all three of the above criteria are met with respect to survival, growth, and establishment of connections, do the grafted cells alter the functional status of the host brain? This question also involves the consideration of mechanisms of action that parallel those found in the CNS (that is, synaptic vs. diffuse release of substances through either direct interaction with nerve fibers or a more diffuse hormone-like influence).
Numerous methodological advancements were made during this period of time. Although the first grafting studies used direct placement of solid grafts, better results were achieved when cavities were formed first, which permitted a degree of vascularization prior to later placement of the fetal graft. 67 Ventricular sites also proved effective for a number of studies, including our own examinations of the endocrinologically important vasopressin grafts in Brattleboro rats. 26"66 This technique, as cited above, was first explored effectively by Flerk6 and Szent/lgothai.~s Important observations were also made with respect to the age of the donor tissue, particularly by Sieger and Olson 6~ who examined embryonic and fetal tissue from donors of a wide variety of ages. In general, they found that nuclei from the brain stem and spinal cord, which characteristically undergo differentiation early during neural development, provide optimal grafting results at the 15th to 17th day of gestation in a rat pup. Cerebral cortex, which differentiates later, can be grafted up to the final day of gestation, as discussed later. The situation in the primate brain may be significantly different inasmuch as survival of brain-stem tissue was seen over an exceptionally wide period of development from early through late gestation in nonhuman p r i m a t e s . 63"65 Perhaps the most intriguing finding during this decade of discovery was the observation that neural circuits could be reestablished by fetal neural grafts. This was best demonstrated in two separate chemically identified systems: the nigrostriatal dopaminergic system and the septohippocampal cholinergic system. Again, histochemically specific methods of tracing these connections, demonstrating either the transmitter fluorophors or transmitter-related enzymes, clearly facilitated these important findings. Bj6rklund and colleagues 2'4'7 9 performed parallel examinations with the cholinergic septohippocampal system in this series of studies. In their initial experiments, the authors were able to study both monoaminergic and cholinergic axons from transplants of different brain-stem nuclei into the hippocampal formation in an attempt to understand the degree to which these grafted neuroblasts could establish normal chemical-specific patterns of innervation. To better visualize this, the host hippocampi were denervated either surgically or neurochemically. They found that grafts from 16-and 17-day-old fetuses survived and sent axons along the route of cholinergic and noradrenergic pathways to the hippocampus. A remarkable specificity to the growing axons was seen with respect to their ultimate terminal patterns. Basically, these fibers formed typical septohippocampal or ceruleal hippocampal patterns which closely paralleled the normal patterns. Bjrrklund and colleagues made three fundamental observations with respect to the question of specificity. First, the grafted noradrenergic axons retained the capacity to grow through the inappropriate terminal zones to reach their appropriate zones in the host hippocampus, which suggests either a retention of trophism by the host target cells or the maintenance of a genetic program for target specificity by the fetal cells. Second, this same phenomenon is found in the cholinergic system. Third, denervation of the appropriate targets appears essential for the growth to occur, as maintenance of these terminal fields effectively blocks this ingrowth. Thus, the concept of trophic factors, retention of genetic program, and highly ordered specificity persisted as dominant themes during this decade of discovery.
Exploration of Models: 1980-1985
Several animal models have been developed to examine the effectiveness of fetal nerve-cell grafts on restoring or improving lost or diminished neurological functions. These include deficits in endocrine, motor, cognitive, and sensory systems. The latter, studied extensively by Ray Lund and his colleagues, 36-38'44 has produced important discoveries in mammals of sufficient magnitude to preclude a detailed summary in the present review. Essentially, Lund and his coworkers have examined the connectivity of transplanted neurons along many points in the visual axis and have found extensive reconnections, patterning, and reorganized cytoarchitectural characteristics that have resulted in a better understanding of neural development.
The idea of modifying an endocrine function, as cited above, was first explored in 1957 by Flerk6 and Szenthgothai. ~8 Grafts of either ovaries or anterior pituitary placed into the third ventricle were able to alter pituitary and peripheral organ function, presumably by the survival of hormone-producing cells and hormone release into the vasculature. Importantly, cells in pituitary grafts demonstrated appropriate staining characteristics and effective hormonal secretion when they were placed into the region of the mediobasal hypothalamus. Here, the normal blood flow of this endocrinologically important part of the brain could influence either the release of pituitary hormones or feedback regulation, as in the case of the ovaries, luteinizing hormone (LH), and follicle-stimulating hormone (FSH). We essentially pursued a similar type of regulatory question by grafting vasopressin-rich portions of the fetal hypothalamus into the third ventricle of Brattleboro rats. These animals, which genetically are deficient in vasopressin synthesis, physiologically are in a state of chronic water imbalance, including diabetes insipidus. We theorized that, if fetal grafts could survive and release vasopressin in the manner analogous to the endocrine release from transplanted anterior pituitary and if this vasopressin gained access to the vascular system, it could then act upon kidney tubules to alter water resorption and increase urine osmolality.
In our early studies, we found that about 20% to 25 % of all Brattleboro rats receiving fetal hypothalamic grafts showed an improved ability to concentrate their urine and decrease fluid intake, beginning as early as 3 days after transplant surgery and lasting the duration of the posttransplant recovery period of either 20 or 40 days. 26"66 Although this percentage of reversal might appear low, it should be noted that these initial studies reported all transplants within the third ventricle regardless of the histological verification of vasopressin neuron survival and the placement of grafts. Subsequent analysis 64 revealed that the successful vasopressin grafts were characterized by the following anatomical features (Fig. 3) . Grafted neurons were found in the third ventricle and appeared fused with the underlying median eminence. The ependymal lining of the floor of the third ventricle had been disrupted, perhaps facilitating the growth of vasopressin-rich axons from the graft into the underlying well-vascularized hypophysiotrophic area. Blood vessels from this region were continuous with blood vessels in the graft, representing either rapid growth of the portal vasculature into the graft or anastomosis with existing capillaries transplanted with these solid grafts. Association of vasopressin-positive terminal fibers with blood vessels was a common feature both within the graft and within the underlying median eminence. The latter observation is of importance because normally the vasopressin axons in this region either pass directly through the median eminence en route to the posterior pituitary or send fibers ventrally to the contact zone of the median eminence. Thus, the appearance of perivascular vasopressin fibers surrounding the prominent blood vessels of the portal system was unusual. Another interesting feature of the vasopressin grafts was that invariably vasopressin neurons were seen at the interface between the graft and host tissue as well as within the underlying tissue as far ventrally as the pituitary stalk. This polarity of neuronal perikarya in the direction of the pituitary gland suggested a migration of fetal neuroblasts through the transplant and into the host tissue. Migration is a common feature of neuroblasts and immature neurons and appears to be retained to some degree following transplantation. 11.28.43.57 Thus, there appears to be cor- respondence between functional reversal in these vasopressin grafts in Brattleboro rats and the following characteristics: proper placement of the graft, presence of vasopressin neurons, association of blood vessels with vasopressin terminals, and possibly migration of vasopressin neurons into an appropriate interface with the host brain.
Additional noteworthy features of these grafts were observed. A second population of vasopressin-rich neurons and their terminal networks was identified. These neurons corresponded to neurons of the suprachiasmatic nucleus, which contains parvicellular vasopressin neurons. This nucleus is not believed to be involved in water balance and is not known to extend projections to the neurohypophysis. Interestingly, this group of vasopressin neurons did not show evidence of migration and, unlike the magnocellular vasopressin neurons, did not send axons toward the underlying median eminence. This infers a specificity with respect to potential connections between transplanted, chemically identified nerve cells and appropriate targets.
Recent studies by Wiegand and Gash 75 have substantiated this initial observation of vasopressin cell specificity. In these later studies, several different vasopressin neuronal cell types have been grafted with the finding of retention of distinct cellular morphology and cytoarchitectural characteristics of donor neuronal groups. Moreover, appropriate projections of these different groups appear to be retained with respect to appropriate targets. For example, suprachiasmatic vasopressin neurons were found to only innervate targets that normally receive afferent projections from this nucleus. Thus, the early vasopressin grafts served as useful models not only for the establishment of hormonal release but also for the support of basic principles of neural transplantation. Obviously, the ventricular cavities provided a supportive milieu for fetal cell growth and the rich vascular bed of the median eminence appeared to be pivotal to the functional reversal seen in Brattleboro rats. The specificity retained by fetal cell groups for their appropriate targets, and probably the receptivity of those target areas to these incoming fibers, were in evidence as well. Also, the Brattleboro rat provided the first functional model system that did not require the establishment of neuronal deficits through the use of surgical and biochemical lesions or other interventions prior to grafting.
An interesting follow-up to these initial vasopressin studies has been the work of Dorothy Krieger, Marie Gibson, Ann Silverman, and their colleagues employing another genetic mutant, the so-called "hypogonadal mouse. ''2v'62 Mice, homozygous for the hypogonadal mutation, failed to show any signs of postnatal, gonadal, or secondary reproductive organ development. Sexual differentiation, importantly, proceeds normally prenatally. Thus, this animal is primed for the development of its reproductive system, but fails to do so because of the lack of luteinizing hormone-releasing hormone (LHRH) which governs pituitary LH and FSH release. In their experiments, areas that contain L H R H neurons, specifically the preoptic area, were transplanted from normal mouse fetuses to the third ventricle of the hypogonadotrophic mice. Their first studies, which now have been confirmed and extended, demonstrated that implantation of the fetal preoptic area into male hosts resulted in testicular maturation and descent into the scrotum. Immunoassays have revealed significant concentrations of L H R H immunoreactivity in the host brain and, more recently, pulsatile release of LH into the systemic circulation has been identified. Reproductive competency also has been achieved in both males and females. Histological examination has revealed grafted L H R H neurons and their fibers in the host's median eminence. Interestingly, as few as three to five identifiable neurons have been seen in animals which showed reversal of function. This may have significant implications with respect to the minimum number of neurons necessary for functional reversal following transplantation. While this number can only be estimated in most experiments, the relatively low numbers of surviving neurons seen in both the LHRH and vasopressin experiments suggest that the nervous system perhaps has an overabundance of cells in any given nucleus such that a significantly reduced number may be able to successfully maintain basal operation. This, however, may be unique to those endocrine neurons that normally function through a diffuse hormonal release instead of the point-to-point synaptic regulation.
The model system that has received perhaps the greatest attention during this period is the nigrostriatal dopaminergic pathway, which is involved in the mediation of normal motor activity. Because of the importance of this system for therapeutic considerations of Parkinson's disease, numerous investigators have explored animal models (usually in rodents) of nigrostriatal damage produced by the neurotoxin, 6-hydroxydopamine. The dopamine projections to the caudate putamen in rats are important for the control of numerous behaviors. Bilateral destruction of the substantia nigra in rats produces a generalized akinetic syndrome that includes interruption of eating, drinking, and grooming as well as other features reminiscent of the hypokinesia of parkinsonism. 7~
A very useful paradigm for quantitation of nigrostriatal deficits was first described by Ungerstedt, 7~-73 who found that unilateral lesions of the nigrostriatal pathway resulted in turning movements away from the side of the lesions, which could be measured quantitatively on a rotometer. These directional changes are transient over a period of several days, after which these animals appear essentially normal. However, the lesioned animals developed a dopamine denervation hypersensitivity that was revealed by the administration of the dopamine receptor agonist, apomorphine. Apomorphine stimulated rotation contralateral to the side of the lesion, while amphetamine, which stimulates dopamine release, resulted in rotational behavior ipsilateral to the side of the lesion (Fig. 4) . Freed and his coworkers, j9'2~ in an innovative series of experiments, utilized these rotational characteristics of the unilaterally lesioned, pharmacologically stimulated rat to test the potential for behavior reversal following grafting of either fetal dopamine neurons or adrenal medullary cells. They found that fetal nigral grafts reduced the apomorphine-induced rotational behavior in comparison to findings in control animals that received grafts of presumably inert sciatic nerve, although these control grafts did produce small but statistically insignificant reductions in rotation. The authors then showed that grafts of other CNS tissue, including optic tectum and cerebral cortex, did not provide significant alteration in rotational behaviors, supporting further the proposition that the dopamine of the grafted nigrostriatal system was responsible for the observed change. Although the degree to which rotational behavior changed was not extraordinary, these findings suggest that nigrostriatal function can be altered with nerve-cell grafts. These investigators also examined the effectiveness of grafts of other cells, specifically adrenal medullary cells, which synthesize dopamine as a precursor to their releasable products, norepinephrine and epinephrine. In these experiments, some improvement in rotational behavior was reported; however, it was not as robust as that found following fetal nerve-cell grafting.
Several additional important features of nigrostriatal grafting have been discovered by Bj6rklund and his colleagues. First, they have unequivocally demonstrated the connectional anatomy of this circuit, both at the light microscopy and the electron microscopy levels. 7 They also have shown that the sensory neglect present in these models can be improved following grafting, and they have advanced our knowledge of optimal grafting techniques, including the use of cell suspensions which produced less damage than solid grafts, either directly into the parenchyma or into preformed cavities. 6,22,59
The Next Frontier: 1986 On
Although the findings in rodent models of dopamine deficiency have excited great interest, these models only partially represent the complex symptomatology present in clinical parkinsonism. Accordingly, the applicability of rodent models to human Parkinson's disease is less clear than that of nonhuman primates, which more closely resemble the human situation and have the potential of providing more accurate models of the disease. 56 While this provides a rationale for examining the model described below, it in no way is intended to detract from the pivotal significance of these initial studies in rodents which demonstrated survival, growth, connectivity, and function of grafted fetal neurons into a dopamine-deficient system.
In primates, it is now well known that the toxin MPTP ( 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) produces behavioral and anatomical alterations that closely mimic those seen in human parkinsonism? 3 This toxin was injected intravenously by drug abusers in California, who shortly thereafter developed signs of parkinsonism. This finding has led to an extensive literature on the form of action of MPTP. This toxin is converted enzymaticaUy to a form (MPP+) highly toxic to dopamine neurons, through oxidation by monoamine oxidase B (MAO-B). Inhibitors of MAO-B, such as Deprenyl, have been shown to be effective in blocking this conversion and in preventing toxininduced degeneration. ~1 The MPP+ form is concentrated in dopamine neurons by a competitive reuptake mechanism against a strong concentration gradient. Neurons that contain the pigment melanin appear to be more susceptible to the effects of MPP+ than are nonpigmented cells. Thus, damage has been found both within the dopaminergic nigrostriatal system and the noradrenergic locus ceruleus. Redmond and his colleagues ~4~5 have utilized this toxin to produce signs of parkinsonism in African green monkeys. Relative measures of homovanillic acid (HVA), a primary dopamine metabolite, in the cerebrospinal fluid (CSF), and histofluorescence postmortem analyses of brain have revealed specific loss of nigrostriatal dopamine neurons. Motor and behavioral changes observed following MPTP treatment in monkeys essentially appeared to shorten the natural time course of Parkinson's disease, as seen in humans, from many years to several weeks. This is an interesting aspect of a model of aging which corresponds well to the increased lipofuscin seen within the nigrostriatal system in these same monkeys. Over this relatively short time span following injection of the drug, a generalized slowing of movement was noted and slight tremors were seen, followed by progressive akinesia, rigidity, difficulty in initiating movement, and postural and resting tremors. Episodes of freezing during movement as well as a characteristic flexed posture were seen. These signs progressively worsened with time. Numerous other similarities to Parkinson's disease were seen. 56
These monkeys provided the opportunity for testing the efficacy of fetal nerve-cell grafts to reverse these signs of Parkinson's disease. Little information existed in the literature, however, to support the feasibility of fetal nerve-cell grafting in primates. To the contrary, Morihisa, eta/., 47'48 attempted embryonic substantia nigra implants into two rhesus monkeys, which previously had been subjected to a 6-hydroxydopamine neurotoxic lesion unilaterally in the substantia nigra. However, neither animal that received the fetal nigral graft was found to contain fluorescent catecholamine neurons within the grafted region. 47'48 Whether cells were not found because of technical reasons related to the histochemical procedure or because of failure of fetal cells to survive cannot be determined unequivocally, as the histochemical procedure used for the two fetal grafts was apparently less than optimal (see discussion by Olson of Morihisa, et al.48) . Additional animals examined by these same investigators following transplantation of the adrenal medullary cells exhibited small numbers of fluorescent cells (ranging from less than 10 per graft site to about 200 at one graft site). The authors generally dismissed the lack of successful grafting as due to immunological or mechanical problems (the latter related to placement within the ventricular system). In our own studies, we have found that neither of these two factors presents a problem, as described below. Gash, et al., 24 in 1985 presented the first experimental evidence of grafting of peripheral neurons into monkey brain. They also described grafts of cholinergicproducing neuroblastoma cells. Autoradiographic labeling with tritiated thymidine was incorporated into the experimental paradigm as a marker for the actively dividing neuroblastoma cells, which then were rendered amitotic with appropriate inhibitors. Numerous acetylcholinesterase-positive and radiographically labeled cells were present near the injection sites in the hippocampal region. One of two monkeys receiving autonomic ganglia grafts showed acetylcholinesterase-positive patches and processes, while the other suffered from an inflammatory reaction which made staining impractical. These two early studies represent the first attempts to graft these cells in primates and, although the results were limited, they did offer useful observations with respect to the feasibility of fetal nerve-cell grafting in monkeys.
Concurrently, the first clinical tests were being performed in Scandinavia, as presented initially by Backlund, et al., ~ in 1985. These experiments consisted of adrenal autograft placement unilaterally into the parenchyma of the striatum of two parkinsonian patients, a 55-year-old man with an 8-year history of parkinsonism and a 46-year-old woman with a 5-year history of symptoms. In neither case was any significant improvement in parkinsonian signs noted, although the second patient showed freer movement of both arms beginning 2 days after surgery. Tremor and hypokinesia were absent until the 4th postoperative day when the rigidity returned and L-dopa was reinstated in increasing doses.
At 2 weeks after surgery, the second patient suffered from periods of paranoia and the hypokinesia appeared to be more pronounced. Over the next 2 weeks, the patient returned to her preoperative state and L-dopa therapy was reinstated. Even though the positive effects of the Swedish studies were difficult to quantify, several other groups have initiated clinical trials using the adrenal transplant approach. Madrazo and colleagues 39 in Mexico City have published a preliminary report on eight patients receiving adrenal medulla autografts to the caudate nucleus using an open microsurgical procedure in which the adrenal fragments are partially exposed to CSF. Their younger patients (three of the patients were under 50 years of age) reportedly showed dramatic decreases in rigidity and tremor which lasted for the 10-month duration of their study. Less dramatic but significant improvements were also reported for their five patients over 50 years old (I Madrazo, personal communication, 1987) . A similar approach and like results have been obtained by Shou-Shu, et al. (personal communication, 1987) , at the Capital Institute of Medicine in Beijing, China, in their study on adrenal medullary autografts in four parkinsonian patients. Since both studies are still in progress and only preliminary subjective reports of their findings are available, it is too soon to judge whether the autograft approach is truly beneficial to the patient and whether long-term side effects may ensue from this treatment.
Redmond, et al., 55'56'63'65 chose to study the potential for fetal dopaminergic nerve-cell grafts to alter MPTPinduced parkinsonism. In an initial experiment, 19 African green monkeys were characterized for the degree of MPTP-induced parkinsonian syndrome. Three animals were chosen as recipients of fetal neural transplants. Two of these animals received multiple solid grafts into 18 sites in the striatum, bilaterally. A third animal received fetal substantia nigra grafts into the cerebral cortex as a control, and also grafts of hypothalamic dopamine neurons and noradrenergic pontine neurons into the striatum and lateral ventricle ( from either late or early gestational fetuses. In one experiment (left), cells derived from a single fetus were transplanted simultaneously into two adult host monkeys (S092, S054) that exhibited signs of experimental parkinsonism as induced by MPTP. Solid grafts were implanted into multiple sites (1-6) in the striatum as illustrated in the dorsal and coronal views. A third parkinsonian monkey (S 114, right) received fetal cells from substantia nigra (s. nigra) into only the anterior sites (Sites 1 and 2 ). These nigral grafts were placed bilaterally into the cingulate cortex, but not the striatum. The two caudal sites (Sites 5 and 6) received implants into the striatum of either hypothalamic dopamine neuroblasts or noradrenergic cells from the locus ceruleus. CC = corpus caltosum; Cd = caudate nucleus; IC = internal capsule; Pt = putamen; S = septum. Neurochemical indices of dopamine function were measured and behavioral ratings of tremor, effect of intention, freezing, difficulty in initiating movement, and other spontaneous behaviors were scored throughout the entire testing period. The two monkeys that received grafts of fetal substantia nigra into the striata showed significant improvement (decreases in parkinsonian signs during a 10-week postoperative observation and recovery period). Measurement of HVA concentrations in the CSF 18 days after transplantation revealed increases of 52% and 35% of baseline in these two monkeys compared to a mean of 19% of baseline in four MPTP-treated animals that did not receive transplants. These values had risen to 89% and 40% at 10 weeks after grafting. Improvement in these measurements was not seen in a control monkey that received dopamine nigral neurons grafts into the cerebral cotrex. Immunohistochemical analysis revealed the presence of well-defined grafts containing dopaminergic neurons and fiber systems, as well as numerous more widely dispersed cells in the host striata in each of the monkeys which showed behavioral and neurochemical improvement. Graft placements were easily identified such that transplanted dopaminergic neurons could be located unequivocally within a mass of grafted tissue (Figs. 6  and 7 ). Cells seen outside the region of the grafted tissue • 450. C: Enlargement of area shown in A. Extensive fiber outgrowth (arrows) is seen from more isolated cells in the dorsal part of the graft. Interestingly, the axons and dendrites from these neurons did not appear to extend beyond the graft-host interface, suggesting the possibility of target specificity for these nigral neurons which do not normally innervate cingulate cortex, x 600.
were attributed to a fetal source by their numbers or morphology, both being distinct from the appearance of endogenous striatal neurons. In each of these animals, examination of the host nigrostriatal system revealed major degeneration of dopaminergic neurons in the substantia nigra and terminal networks in the striatum. It was interesting that cell survival in the control animal reflected an organotypic level of organization. Specifically, nigral grafts in the cortex of the control monkey revealed the presence of numerous dopaminergic neurons with fiber systems reminiscent of dendrites of the zona reticulata of the normal substantia nigra (Fig. 8) . These dendrites did not extend beyond the graft-host interface, which suggests a degree of specificity of the growth pattern. Similarly, the hypothalamic grafts in this animal showed small bipolar neurons reminiscent of those of the tuberoinfundibular dopamine system, whereas the pontine grafts showed medium and larger multipolar neurons, which resembled the locus ceruleus-subceruleus complex both cytoarchitecturally and positionally. 63 The combination of behavioral improvement, neurochemical recovery, and morphologically identifiable dopaminergic neurons in these three animals suggests that grafting of fetal substantia nigra into parkinsonian primates is an approach that has considerable merit with respect to possible clinical intervention of Parkinson's disease. The correspondence between cell survival and behavioral improvement was quite good in each monkey. It seems unlikely that the improved indices were the result of a spontaneous recovery, because of the correspondence between cell numbers, behavioral improvement, and neurochemical elevations. Thus, this initial study supports the use of fetal nerve cells as a donor tissue for therapeutic intervention in experimental parkinsonism in primates. Although still preliminary, these data also draw attention to the observation that immunological rejection of the tissue did not appear to be a complicating factor, and to the survival of fetal nerve cells from a wide range of gestational ages which may be of significance with respect to the human clinical scientific question in the future. Nevertheless, numerous scientific questions should be addressed before human trials can be considered. Clearly, the question of safety of this procedure over the long-term projected recovery of the parkinsonian patient needs to be determined in nonhuman primates as well as any potential behavioral abnormalities produced by the grafted neurons. It is not known whether immunological rejection would occur over longer survival periods, or whether some environmental factor (perhaps induced by a blood transfusion that might activate lymphocytes) might lead to rejection of the grafts. It is important to determine the optimal developmental age for fetal donor cells because, in this first successful primate experiment, the grafts in the control monkey that received cells from an early gestational donor grew to relatively large proportions within the lateral ventricles, which may have led in part to the death of this monkey. If greater growth potential is retained by the more developmentally immature tissue, then optimal graft size could become a critical factor in determining suitable donor age. Numerous questions exist as to the placement sites for cells: presently, a target site has been chosen that obviates the need to direct long axonal pathways from the sites of origin.
Considerable discussion is needed concerning all aspects of human trials, particularly if fetal donor cells are to be used. According to present legal statutes in most states, the use of nonviable, spontaneously aborted fetal tissue could be considered, 4~ but the cell viability from such cadaver tissue needs to be established. Screening procedures must be developed for prevention of possible transmission of disease through graft-mediated viruses and other pathogens. Numerous ethical and religious concerns should be addressed, and the legal community would most likely be asked to consider questions of liability for any abnormal or antisocial behavior that might be manifested subsequent to a neural grafting approach. Moreover, the idea that conception of an embryo might be sought as a means of providing donor tissue for a relative or acquaintance or that some material gain might be achieved represents a significant concern. Finally, procedures would need to be developed for preserving donor tissue, perhaps in the manner of the cell and donor banks concurrently in use in other areas of medical transplantation.
There are several alternatives to the use of human fetal nerve cells (Table 1) . These include the use of peripheral neural and paraneural tissues (Fig. 9) as well as cultured cell lines. For example, one very interesting and potentially productive line of research involves the attempt to modify paraneural cells (such as those from the adrenal medulla, which embryologically are derived from neuroblasts and ultimately produce catecholamines including dopamine) into neural-like cells for transplantation. Clear examples exist from many laboratories suggesting that nerve growth factor can induce adrenal medullary cells from the rat, TM monkey, 49 and human TM to extend processes and become neuronoform in appearance (Fig. 10) . [69] [70] [71] [72] [73] [74] [75] [76] 1986 , with permission.) adrenal autografts than indicated initially, although these studies are very preliminary at present. Crossspecies grafts represent another possible option. Advances in our understanding of immunosuppression, particularly with the use of cyclosporin A which has been shown to be effective in limiting rejection of grafted neurons between different mammalian species, might be utilized in the future to allow grafting of nonhuman substantia nigra into parkinsonian patients. The reverse of this has occurred with reports of successful grafting of human fetal neurons into rat brain or the anterior chamber of the eye? ~ Thus, one could envision that the use of nonhuman fetal cells could eliminate several concerns, not the least of which is the potential selective or limited availability of human fetal cells for grafting.
It is also possible that cell lines derived from human neuroblastomas might be modified to become amitotic and be stimulated to express a single transmitter substance consistent with the missing or deficient substance seen in parkinsonism and other neurodegenerative disorders. A very interesting approach used by Gash, et al., 25 has been the grafting of amitotic neuroblastoma cells from the IMR-32 cell line into adult African green monkeys. This study demonstrated cell survival of up to 340 days after transplantation and utilized autoradiographic labeling of donor cells (Fig. 11) . The grafted cells remained differentiated, did not revert to a mitotic state, and were not rejected by the host even though the cells were of human origin and thus represented a crossspecies transplant. More recently, Kordower, et al., 32 have demonstrated in rodents that amitotic neuroblastoma cells not only survive transplantation but are capable of reversing some lesion-induced functional deficits. Another concept worth considering is the engineering of cells, perhaps through oncogene insertion, to produce immortal cell lines with specific transmitter characteristics. Presumably, such cells could then be cultured, stored, and made available for transplantation purposes in unlimited quantities.
Summary
Nerve-cell transplantation experiments over the past 15 years have revealed a remarkably plastic nervous system capable of accepting fetal neurons from a variety of brain regions and of supporting the growth and maturation of these neurons with eventual integration into the host brain. Equally remarkable is the retention by the fetal neuroblast of their transmitter phenotype, and indeed their cytoarchitectural destiny which can remain intact even when developing in novel environments. It is clear that numerous factors are responsible for this phenomenon, including various trophic elements, many of which probably remain to be defined. The exploration of technical parameters in rodents, primarily, has established certain principles of neural grafting as they relate to the age of the donor, the source of the tissue, the preparation of the tissue prior to transplantation, the specificity of cell types for integration into target areas, and numerous other factors. The exploration of various models of neurodegenerative disorders, including those in endocrine, motor, cognitive, and sensory systems, has provided an exceptionally diverse array of tests of fetal nerve-cell grafting. The applicability of these procedures to human clinical problems has led to the exploration of alternative cell sources, most notably adrenal medullary cells, for movement disorders. The work has proceeded so rapidly and effectively that it prompted the first human clinical attempts in Scandinavia. These attempts have provided some optimism that neural grafting is a feasible approach in Parldnson's disease; however, permanent improvement has not been noted in any of the first patients treated in Scandinavia. Subsequent clinical experiments in China and Mexico have reported better results. The successful reversal of toxin-induced parkinsonism in monkeys using fetal substantia nigra grafts might prompt the further consideration of the use of fetal neural tissue in human parkinsonism, at first probably derived from nonviable, spontaneously aborted human fetuses. Considering the great number of parkinsonian patients who face the prospect of a progressive disease which usually will become refractory to L-dopa therapy, one could argue that it is more humanistic to consider utilizing, instead of discarding, available tissue sources for this procedure. Nevertheless, numerous technical questions must be addressed before the procedure can be demonstrated to be both effective and safe over the long-term prospect of clinical therapy. Perhaps most importantly, prior to clinical interventions the first application of this approach should benefit from extended and inclusive discussion of all societal, scientific, ethical, and legal issues related to the use of human fetal tissue. Finally, every effort should be made to examine the feasibility of utilizing donor cells derived from nonfetal human sources as alternatives.
